The cardiovascular benefits of SGLT2 inhibitors were an unexpected finding fromthe EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2Diabetes Mellitus Patients) trial, which showed that empagliflozin was associatedwith a significant reduction in the risk of HF hospitalization and cardiovasculardeath in patients with type 2 diabetes and established cardiovascular disease[21]. Here, SLC5A2 is linked to diabetes mellitus.